1 Introduction to Research & Analysis Reports
1.1 Drug-Resistant Tuberculosis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drug-Resistant Tuberculosis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drug-Resistant Tuberculosis Treatment Overall Market Size
2.1 Global Drug-Resistant Tuberculosis Treatment Market Size: 2021 VS 2028
2.2 Global Drug-Resistant Tuberculosis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drug-Resistant Tuberculosis Treatment Players in Global Market
3.2 Top Global Drug-Resistant Tuberculosis Treatment Companies Ranked by Revenue
3.3 Global Drug-Resistant Tuberculosis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Drug-Resistant Tuberculosis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drug-Resistant Tuberculosis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Drug-Resistant Tuberculosis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Drug-Resistant Tuberculosis Treatment Market Size Markets, 2021 & 2028
4.1.2 First-Line Anti-TB Drugs
4.1.3 Second-Line Anti-TB Drugs
4.1.4 Others
4.2 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
4.2.1 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
4.2.2 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
4.2.3 By Type - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drug-Resistant Tuberculosis Treatment Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Online Pharmacy
5.1.4 Retail Pharmacy
5.1.5 Others
5.2 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
5.2.1 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
5.2.2 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
5.2.3 By Application - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Drug-Resistant Tuberculosis Treatment Market Size, 2021 & 2028
6.2 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue & Forecasts
6.2.1 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2022
6.2.2 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue, 2023-2028
6.2.3 By Region - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
6.3.2 US Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
6.4.2 Germany Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.3 France Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.4 U.K. Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.5 Italy Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.6 Russia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.4.8 Benelux Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
6.5.2 China Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5.3 Japan Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.5.6 India Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
6.6.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.6.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028
6.7.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.7.3 Israel Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
6.7.5 UAE Drug-Resistant Tuberculosis Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Sanofi
7.1.1 Sanofi Corporate Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.1.5 Sanofi Key News
7.2 Novartis AG
7.2.1 Novartis AG Corporate Summary
7.2.2 Novartis AG Business Overview
7.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.2.5 Novartis AG Key News
7.3 Endo International plc
7.3.1 Endo International plc Corporate Summary
7.3.2 Endo International plc Business Overview
7.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.3.5 Endo International plc Key News
7.4 CMP Pharma
7.4.1 CMP Pharma Corporate Summary
7.4.2 CMP Pharma Business Overview
7.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.4.5 CMP Pharma Key News
7.5 STI Pharma LLC
7.5.1 STI Pharma LLC Corporate Summary
7.5.2 STI Pharma LLC Business Overview
7.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.5.5 STI Pharma LLC Key News
7.6 Akorn Incorporated
7.6.1 Akorn Incorporated Corporate Summary
7.6.2 Akorn Incorporated Business Overview
7.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.6.5 Akorn Incorporated Key News
7.7 Lupin
7.7.1 Lupin Corporate Summary
7.7.2 Lupin Business Overview
7.7.3 Lupin Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.7.5 Lupin Key News
7.8 Johnson & Johnson Services Inc.
7.8.1 Johnson & Johnson Services Inc. Corporate Summary
7.8.2 Johnson & Johnson Services Inc. Business Overview
7.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.8.5 Johnson & Johnson Services Inc. Key News
7.9 Macleods Pharmaceuticals Ltd
7.9.1 Macleods Pharmaceuticals Ltd Corporate Summary
7.9.2 Macleods Pharmaceuticals Ltd Business Overview
7.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.9.5 Macleods Pharmaceuticals Ltd Key News
7.10 Pfizer Inc
7.10.1 Pfizer Inc Corporate Summary
7.10.2 Pfizer Inc Business Overview
7.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.10.5 Pfizer Inc Key News
7.11 Hikma Pharmaceuticals PLC
7.11.1 Hikma Pharmaceuticals PLC Corporate Summary
7.11.2 Hikma Pharmaceuticals PLC Business Overview
7.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.11.5 Hikma Pharmaceuticals PLC Key News
7.12 Lannett
7.12.1 Lannett Corporate Summary
7.12.2 Lannett Business Overview
7.12.3 Lannett Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.12.5 Lannett Key News
7.13 Mylan N.V.
7.13.1 Mylan N.V. Corporate Summary
7.13.2 Mylan N.V. Business Overview
7.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.13.5 Mylan N.V. Key News
7.14 Teva Pharmaceutical Industries Ltd
7.14.1 Teva Pharmaceutical Industries Ltd Corporate Summary
7.14.2 Teva Pharmaceutical Industries Ltd Business Overview
7.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.14.5 Teva Pharmaceutical Industries Ltd Key News
7.15 Fresenius Kabi AG
7.15.1 Fresenius Kabi AG Corporate Summary
7.15.2 Fresenius Kabi AG Business Overview
7.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Major Product Offerings
7.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue in Global Market (2017-2022)
7.15.5 Fresenius Kabi AG Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Drug-Resistant Tuberculosis Treatment Market Opportunities & Trends in Global Market
Table 2. Drug-Resistant Tuberculosis Treatment Market Drivers in Global Market
Table 3. Drug-Resistant Tuberculosis Treatment Market Restraints in Global Market
Table 4. Key Players of Drug-Resistant Tuberculosis Treatment in Global Market
Table 5. Top Drug-Resistant Tuberculosis Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drug-Resistant Tuberculosis Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drug-Resistant Tuberculosis Treatment Product Type
Table 9. List of Global Tier 1 Drug-Resistant Tuberculosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drug-Resistant Tuberculosis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drug-Resistant Tuberculosis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Drug-Resistant Tuberculosis Treatment Product Offerings
Table 32. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Novartis AG Corporate Summary
Table 34. Novartis AG Drug-Resistant Tuberculosis Treatment Product Offerings
Table 35. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Endo International plc Corporate Summary
Table 37. Endo International plc Drug-Resistant Tuberculosis Treatment Product Offerings
Table 38. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 39. CMP Pharma Corporate Summary
Table 40. CMP Pharma Drug-Resistant Tuberculosis Treatment Product Offerings
Table 41. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 42. STI Pharma LLC Corporate Summary
Table 43. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product Offerings
Table 44. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Akorn Incorporated Corporate Summary
Table 46. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product Offerings
Table 47. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Lupin Corporate Summary
Table 49. Lupin Drug-Resistant Tuberculosis Treatment Product Offerings
Table 50. Lupin Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Johnson & Johnson Services Inc. Corporate Summary
Table 52. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product Offerings
Table 53. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Macleods Pharmaceuticals Ltd Corporate Summary
Table 55. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product Offerings
Table 56. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Pfizer Inc Corporate Summary
Table 58. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product Offerings
Table 59. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Hikma Pharmaceuticals PLC Corporate Summary
Table 61. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product Offerings
Table 62. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Lannett Corporate Summary
Table 64. Lannett Drug-Resistant Tuberculosis Treatment Product Offerings
Table 65. Lannett Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Mylan N.V. Corporate Summary
Table 67. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product Offerings
Table 68. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Teva Pharmaceutical Industries Ltd Corporate Summary
Table 70. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product Offerings
Table 71. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Fresenius Kabi AG Corporate Summary
Table 73. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product Offerings
Table 74. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Drug-Resistant Tuberculosis Treatment Segment by Type in 2021
Figure 2. Drug-Resistant Tuberculosis Treatment Segment by Application in 2021
Figure 3. Global Drug-Resistant Tuberculosis Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drug-Resistant Tuberculosis Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drug-Resistant Tuberculosis Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drug-Resistant Tuberculosis Treatment Revenue in 2021
Figure 8. By Type - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 12. US Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 24. China Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drug-Resistant Tuberculosis Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Lupin Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Lannett Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report